Building Diagnostics Without Building Hardware: Checktor’s Strategic Play скачать в хорошем качестве

Building Diagnostics Without Building Hardware: Checktor’s Strategic Play

In this episode of Diagnosing Dx, I’m joined by ⁠Jake Lesinski⁠, Co-founder and CEO of ⁠Checktor Biosciences⁠, an ETH Zurich spin-out building a CRISPR-based chemistry platform designed to upgrade existing diagnostic systems rather than replace them. We explore why speed, decentralisation, and practical integration, not hype — will define the next wave of molecular diagnostics. Jake shares how Checktor is approaching CRISPR from a clinical and commercial perspective, why matching PCR-level performance matters, and how distribution strategy can make or break even the strongest science. This conversation is a grounded look at how diagnostics companies can scale responsibly, partner intelligently, and deliver real value to patients and healthcare systems. Key takeaways: 🔹 Why rapid, accurate diagnostics remain one of healthcare’s biggest unmet needs 🔹 How CRISPR is finally finding its footing in real clinical workflows 🔹 Why upgrading existing diagnostic infrastructure beats starting from scratch 🔹 What founders need to understand about partnerships, validation, and scale 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics. #Diagnostics #CRISPR #MolecularDiagnostics #Biotech #LifeSciences #MedTech #DecentralisedTesting #PointOfCare #HealthcareInnovation #ClinicalDiagnostics #ETHZurich #StartupBiotech #SciencePodcast